Biotech and Money
Biotech and Money is a growing influential community of senior life science decision makers. We are a catalyst for dialogue, debate and deal making to help lead growth in healthcare investment and the building of billion dollar healthcare businesses.
We are determined to forge a fundamentally better way to promote and facilitate investment, financing, partnerships and deal making in healthcare.
Mr Matt PullanSenior Vice President
Crystec applies the latest supercritical fluid (SCF) technology to improve the design and performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical and biopharmaceutical industries, contributing to human health by enabling new and more effective therapies. Crystec SCF technology can be applied to small and large drug molecules in a range of dosage forms. Our expertise includes designing the world’s first SCF engineered drug (Semprana – inhaled delivery for migraine), which is expected to launch later this year.
Our services include crystal form screening and particle design (including composite particles and scalable co-crystals), addressing issues of poor solubility and stability, improved delivery, and product enhancement in support of lifecycle management. Our process is scaled to GMP manufacturing levels.
We also have a strong product pipeline, focused on repurposing existing therapies. These assets are in a number of therapeutic areas including urge incontinence, women’s health, fungal infections, and malaria, and are currently available for out-licensing.
For more information on our technology or assets please visit www.crystecpharma.com or contact Catherine Hunter, Business Development Director (firstname.lastname@example.org).
Miss Catherine HunterBusiness Development Director
CTRL Group Ltd
New technologies have the potential to transform healthcare and medical research by increasing efficiency and creating more personalised medicine.
Ctrl Group is a team of designers, researchers, software developers and healthcare experts who work internationally with healthcare companies and providers who want to use new technology to improve people’s health. We create products and services that are effective, engaging and safe.
Mr Ben FehnertFounder
Department for International Trade, London Region
Exhibiting at booth #57 with the following companies:
Biotech and Money
CTRL Group Ltd
Richmond Pharmacology Limited
Strategy in Life Sciences
View the Department for International Trade's brochure for Bio-Europe here.
Mr Chris ParsonsInternational Trade Adviser
Mr Rory SmithInternational Business Advisor
Edinburgh Molecular Imaging Ltd
Using its proprietary platform technology, Edinburgh Molecular Imaging is developing a pipeline of highly novel in vivo optical imaging agents that can be used to diagnose disease and alter the landscape of precision medicine.
EM Imaging also has a portfolio of agents addressing a number of unmet medical needs.
Mr Ian WilsonChief Executive Officer
First Derivatives plc
First Derivatives occupies a niche position within the market place offering a combination domain knowledge of financial markets and expertise in financial services technologies. We provide innovative trading platforms for low latency, high volume environments across all asset classes including FX, equity, fixed income and commodities - providing credit, market, operational, liquidity, capital adequacy and stress testing solutions. The Company scopes, designs, develops, implements and supports a broad range of mission critical data and trading systems across front, middle and back-office operations.
Mr Jamie ConlonBusiness Development
Mr Gary ConnollyBusiness Development
Formuli is a Business Development and Licensing Agency that helps companies find partners for their technologies and products. At Bio Europe, Formuli is presenting the following opportunities for partnering:
1. A Potent Novel Anti-Inflammatory agent with an excellent efficacy/safety profile for use alone, or in combination with Steroids.
2. An Invisible Transdermal Spray-On patch technology focussing on ADHD, Alzheimers, Parkinsons and Pain, but with the potential for broad utility.
3. A Once Weekly Oral Tablet formulation of Aripiprazole for Bipolar Disorder, Schizophrenia and MDD.
4. A Blood Brain Barrier Transport Mechanism with excellent early results in NeuroOncology but with the potential for broad utility.
Dr Russ PendletonCEO
Image Analysis Group is global group of companies with expertise in clinical R&D, clinical trial design, regulatory and financial strategy for biotechnology companies involved in clinical research of immunooncology, inflammatory and degenerative diseases.
Dr Olga KubassovaCEO
Mirador Analytics is an analytics and consultancy firm providing drug commercialization assessment and launch planning services to biopharma organizations around the world. We are a UK and North American-based firm with extensive expertise in: Asset Evaluation; Pricing and Market Access; Asset and Portfolio Prioritization; KOL Mapping; Market and Competitor Intelligence; Market Research; Insight and Analytics; Medical and Regulatory Affairs; Business Development; and Commercialization Planning.
Mirador Analytics is unique in their combined analytical and consultancy offering. In contrast to other analytical organizations, our combined analytical and consultancy services enable us to bring industry-specific relevance to our clients’ analytical and data-driven needs. Mirador Analytics' team members have all worked on our clients’ side of the business, allowing us to fully appreciate the intricacies of the pharmaceutical sector and our clients’ specific requirements. Similarly, and in contrast to other consultancy organizations, our proprietary analytical tools provide the analytical rigor that is vital to our clients’ commercialization requirements.
We can support our clients with the use of our proprietary prevalence-based Asset Evaluation Tool and Individual Identification Database (I.I.D), along with our extensive consultancy services. With your internal data and insights, along with external data, we apply our extensive experience and knowledge to generate clear outputs that are relevant to you and your organization.
Mirador Analytics’ Wraparound Services:
Mirador Analytics offers a complete wraparound service built around our analytical tools. Our extensive expertise in the pharmaceutical sector enables us to support you with data inputs, assumptions and output interpretations. From developing payer frameworks and target product profiles to competitive landscape reviews, the Mirador Analytics’ team has the international experience to assist your organization in achieving its strategic objectives. Our expertise spans across Medical Affairs; Pricing and Market Access; Insight and Analytics; Strategy; Marketing; and Business Development. Our working relationship with you is built upon collaboration; we work closely with you at each stage of the project and remain mindful of your specific requirements. In working with Mirador Analytics, you can expect the delivery of outputs that are data driven, relevant, and supported by analytical rigour and insights from team members who have sat on your side of the business.
We combine our analytical expertise with:
- Experience in how your organization functions, with team members who have worked on your side of the business.
- Integrated services to better serve the needs of your organization.
- The knowledge to generate clear outputs, which are relevant to you and your organization, using a combination of your internal company data and external data sources.
- Valuing collaboration – we have an ability to listen and highly encourage client input at every stage of our journey together.
Mr Jamie BlackportCEO
Dr David JohnsonDirector, Biopharma Analytics and Business Development
Mironid Ltd is an innovative drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our current drug discovery pipeline is aimed at developing novel treatments for degenerative kidney diseases, chronic inflammatory diseases and cancer. Mironid is currently building and progressing a pipeline of early stage drug discovery programmes that are initially targeted at cAMP degrading phosphodiesterase enzymes. These will generate novel and differentiated therapies for a range of therapeutic indications in areas of high unmet medical need.